Member Info for Jonah58

I accept that point, BB, but it only starts to make comercial sense when the metal price exceeds a certain level above which the whole project becomes economical. We are still in the dark about that.

Posters do well to highlight the value of Vanadium in our tailngs, but these figures are difficult to evaluate without an estimate of the cost of extracting it. The disolved gold in sea water is worth millions, but it would cost billions to extract it. I don't even know how we are planning to get the vanadium out. Is it a leaching process, as suggested by previous BMR news releases, or a gravity separation technique as, I believe, is planned at other tailings projects in Namibia?

Whatever process is being considered, it will need, as a minimum, an enviro license which can take a while to come through. Are we in a position to at least apply for this yet?

Until answers to these questions are known, gloating over the value of the buried treasue falls under the heading of 'wishful thinking', though the steady rise in Vanadium prices can be nothing but good.

Absolutely, Saxon, and the outcomes will be extremely interesting, but it will lack the rigour which the regulatory authorities hold in such high regard!

Retour, I really appreciate your positive attitude, but when you set up a trial in a certain way youhave to accept the result and not resort to numerous sub-group analyses to get you out of trouble. A sub analysis of the breakthrough trial of Streptokinase in myocardial infarction showed that the drug was ineffective in people born under libra and taurus.
I do agree that the sub-group of Europeans (+ Mauritius for some reason) with anti-dsDNA is very interesting, and I would love to see a trial set up de novo in these people, with reduction in the dose of steroids needed control the symptoms as a primary end point. I hope the executors of my will see the outcome!

BMR get 12.5% of profits from Kabwe tailings project once capital costs etc have been paid off. This still could be a tidy sum (for zero input and no further risk) if Kabwe succeeds. If not, I agree, they get zilch.

As the fates of BMR, JLP and GLR are now inextricably entwined, I for one, would be happy to see BMR holders with genuine information or interesting points of view posting here. In fact they did do so before BMR delisted and their insight was a lot more valuable than some of the stuff that ends up on this board.

GCM up a bit following another very preliminary Chinese deral. Not too exciting at this stage, but worth mentioning if only to fill the vacuum on this board.

Thanks trojjan. Bluebelly picks up on the same point that interested me (a lot). If we have really cracked fine chrome recovery, that is a very big deal. And (did I hear this correctly at 04.47 ?) we are building two more fine chrome recovery plants, presumably for other players in the chrome industry. Anyone heard of this before the interview?

All good points. I note reduction in steroid requirement was an outcome in the Astra trial "The programme assesses the effect of anifrolumab in reducing disease activity, as measured by the SRI4, decreasing use of oral corticosteroids, improving skin manifestations...," I am not sure whether this was an outcome in our study, but I don't recall any data on titrating steroid dose.

And, as a follow up to my last post, if every new medication historically had to be labelled as an adjunct to standard of care, we would now be treating every syphilitic with mercury (plus additional antibiotics) and every heart failure patient with leeches and ACE inhibitors.

You make an excellent point, Bermuda. Ethically you have to give standard of care treatment, and the close clinical attention afforded to trial patients ensures that they take this medication correctly. It is well known that in normal clinical practice a very high percentage of patients do not adhere well to complex treatment regimens. This partially explains the unexpectedly high placebo response we see in many trials.
As you say, many SLE patients are on steroids and antimalarials with adverse side effect protocols. These drugs are administered when the disease fails to be controlled by simpler medication. I believe it would be ethical to randomise antiDS DNA patients not yet on steroids, but whose introduction is anticipated, to steroid or Lupuzor, but I guess it won't happen. I know several patients who would jump at the opportunity of taking an alternative to steroids.

Good find Whale Oil. I think the insinuation from what Leon has been saying, and from Jubilee's long and chequered history, is that we are trying to forge a strong relationship with a platinum major with a view to processing all their waste. Northam would be an obvious candidate, hence their fortune could be tied up with ours.

Kal, whilst I agree with you that the problem of fine chrome recovery is an old one, the solutions are relatively new with most of the published research appearing within the last two decades. I found a very helpful article (link below) which makes it clear the importance and nature of the problem as well as other matters. For instance I now understand the difficulties that arose when we added third party ore to our feed at DCM. As you say, it looks as though LC is talking about new technology though whether this is sophisticated grevity separation, flotation or something completely new has not been revealed. There are no new pictures of the plant on the website.

"Since most chromite ores are easily beneficiated
with gravity concentration methods, flotation of chromite has not
been widely applied or got commercial acceptance (Atalay and
Ozbayoglu, 1992). This is the most essential issue of every gravity
separation circuit in mineral processing plants, which causes loss
of large fraction of the valuable minerals into tailings."

https://www.researchgate.net/publication/241098405_Chrome_ore_beneficiation_challenges_opportunities_-_A_review

Like you, I picked up on this (and can't answer your question). Throughout all the ASA RNSs over the years there has been no mention at all of fine chrome until recently. The building of the fine chrome circuit came as an unexpected surprise. Why so? Perhaps because we were keen to keep it under our hats until at an advanced stage. From what LC said there is quite a bit of fine chrome in these tailings and, presumably, in run of mine ore. If we have developed a new process to retrieve it then that would be big news. All guesswork, as usual with this share however.

References to support my comment re pundits:

https://investingnews.com/daily/resource-investing/precious-metals-investing/platinum-investing/platinum-outlook/

https://www.bullionvault.com/gold-news/buy-platinum-112820171

https://www.statista.com/statistics/254547/precious-metal-price-forecast/

Good RNS. Hernic really is a winner. Some slippage of time lines elsewhere, but progress nevertheless.

Still no approval for the platinum circuit at DCM. I cannot recall such a long delay to get permission for the platinum circuit at Hernic. Maybe platinum prices will improve while this is sorted out. The pundits seem to think so.

Good find, CH. It's interesting that he highlights VWgate as a significant factor in the currently depressed PoP. The diesel engine could certainly do with a bit of PR and I think that's what it is going to get. Modern diesels simply do not justify the current hate hysteria. Seat's eco range of diesels has minimal emissions. Road tax =£0, same with BMW.

Sadiq Khan is introducing 'eco' ratings for cars in London. A=best to H=worst. Audi, Skod, Seat, VW, Mercedes, Mini diesels all rate 'A'.

Time will tell.

Re news/RNS. You could check out recent posts on BMR and make of it what you will.

Board changes. This sentence caught my eye in particular I hope to host Andrew at the opening of our Zambian offices and technical centre which we are launching to support both the Kabwe project as well as our further growth aspirations in Zambia.

Thanks for this link, MH. Northam are not behaving like an outfit who see no future for PGMs! Their investment is huge.